Etelcalcetide
Mechanism :
Etelcalcetide, a synthetic peptide calcimimetic, allosterically activates the calcium-sensing receptor (CaSR) on the parathyroid gland, resulting in decreased PTH secretion, and serum calcium and phosphorus levels in patients with secondary hyperparathyroidism on hemodialysis.
Indication :
- Secondary hyperparathyroidism with chronic kidney disease (CKD) on hemodialysis
Contraindications :
Hypersensitivity to etelcalcetide or any component of the formulation.
Dosing :
Safety and efficacy not established in children.
Adults:
IV: Initial: 5 mg IV bolus 3 times per week at the end of hemodialysis.
Adverse Effect :
Decreased serum calcium, hypophosphatemia, diarrhea, nausea, muscle spasm, prolonged Q-T interval on ECG, cardiac failure, hypocalcemia, vomiting, antibody development.
Interaction :
Cinacalcet: May enhance the hypocalcemic effect of Etelcalcetide.
Hepatic Dose :
No dosage adjustments are recommended.